KCT0008556尚未招募Unknown
Comparison of Human Gut microbiota-derived consortium complex with rifaximin and rifaximin for irritable bowel syndrome patients: A open-label, prospective, randomized controlled trial
Hallym University Medical Center-Kangnam0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •patients (19 years or older) who met the Rome IV criteria for the diagnosis of IBS were eligible to participate.
排除标准
- •The exclusion criteria were previous abdominal surgery except appendectomy and Caesarian section, inflammatory bowel syndrome, and concurrent severe illness (cancer, cardiovascular or pulmonary disease). In addition, patients who had used antipsychotics, antibiotics, and probiotics within the four weeks were also excluded.
研究者
相似试验
招募中
不适用
Investigating the differences in gut bacteria across ageing and in Parkinson's DiseaseParkinson's diseaseNeurological - Parkinson's diseaseNeurological - Studies of the normal brain and nervous systemACTRN12621000006842Helen Macpherson144
招募中
Unknown
A study to analyse relationship between gut microbiome and different types of lung cancersCTRI/2023/04/051268Bhaktivedanta Hospital and Research Institute
已完成
不适用
Efficacy of Human Gut microbiota-derived consortium complex for irritable bowel syndrome patientsKCT0007709Hallym University Medical Center-Kangnam44
进行中（未招募）
1 期
Intestinal flora therapy or antibiotics for primary Clostridium difficile infectioClostridium difficile infectionEUCTR2018-004580-31-NOOslo University Hospital188
招募中
不适用
Differences in the gastrointestinal microbiome signature in chronic obstructive pulmonary disease (COPD)ACTRN12614001286639Peter Wark100